Qualigen Therapeutics Faces Nasdaq Delisting Threat

The latest update is out from Qualigen Therapeutics ( (QLGN) ).

Qualigen Therapeutics, Inc. has received a deficiency notification from Nasdaq due to its failure to timely file its Annual Report on Form 10-K for the year ending December 31, 2024. This delay has led to the company’s non-compliance with Nasdaq’s listing requirements, resulting in a decision to delist its securities unless an appeal is filed by May 1, 2025. The company plans to appeal and aims to regain compliance with Nasdaq’s rules as soon as possible, although there is no assurance of success.

Spark’s Take on QLGN Stock

According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.

Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.

To see Spark’s full report on QLGN stock, click here.

More about Qualigen Therapeutics

YTD Price Performance: -14.76%

Average Trading Volume: 61,729

Technical Sentiment Signal: Buy

Current Market Cap: $2.64M

See more data about QLGN stock on TipRanks’ Stock Analysis page.